Xvivo Perfusion AB (publ) (XVIPF)
OTCMKTS · Delayed Price · Currency is USD
18.00
-0.86 (-4.56%)
Nov 6, 2025, 9:30 AM EST
Xvivo Perfusion AB Market Cap
Xvivo Perfusion AB has a market cap or net worth of $578.65 million as of November 6, 2025. Its market cap has decreased by -61.69% in one year.
Market Cap
578.65M
Enterprise Value
562.42M
Revenue
86.34M
Ranking
n/a
PE Ratio
182.35
Stock Price
$18.00
Market Cap Chart
Since October 8, 2012, Xvivo Perfusion AB's market cap has increased from 56.07M to 578.65M, an increase of 932.00%. That is a compound annual growth rate of 19.53%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Nov 5, 2025 | 578.65M | -58.51% |
| Dec 30, 2024 | 1.39B | 35.52% |
| Dec 29, 2023 | 1.03B | 96.50% |
| Dec 30, 2022 | 523.72M | -42.34% |
| Dec 30, 2021 | 908.22M | -17.47% |
| Dec 30, 2020 | 1.10B | 126.83% |
| Dec 30, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 28, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 29, 2017 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2016 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2015 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Veradigm | 815.18M |
| Elite Pharmaceuticals | 659.64M |
| Glass House Brands | 595.49M |
| Northwest Biotherapeutics | 373.25M |
| American Oncology Network | 326.52M |
| Nika Pharmaceuticals | 311.89M |
| CytoDyn | 308.64M |
| Silence Therapeutics | 294.74M |